Renova is exploring new therapeutic opportunities that have the potential to expand the use of Renova’s gene therapy platform to include several pathologies associated with diabetes and heart failure.
Read MoreRenova Has Prioritized Two Primary Regulatory Pathways Where It Is Poised to Launch Pivotal Human Trials for Its Promising Gene Therapies to Treat Heart Failure and Type 2 Diabetes Mellitus
Read MoreThe Oct. 2-3 hybrid workshop will bridge the gap between critical stakeholders to pinpoint today's challenges and create forward-thinking solutions that enable the cell and gene therapy industry to create and deliver life-saving treatments equitably.
Read MoreThe Global Community of Hematopoietic Cell Transplantation and Cellular Therapy Specialists will Gather for the 2023 Tandem Meetings to Improve the Lives of Patients with Blood-Related Disorders and Solid Tumors.
Read MoreOcyonBio CDMO welcomes cell and gene therapy expert Robert Salcedo who brings over 20 years of expertise in the areas of CMC, operations, and supply chain management and has served in multi-billion-dollar companies operating in biotech, vaccines, and pharmaceutical markets.
Read MoreSingle-use bioreactors market is estimated to attain a CAGR of 20.2% through 2027 owing to various advantages such as reduced cross contamination, cost-effectiveness, flexibility and increased productivity.
Read MoreEvery year, The Medicine Maker, a leading, global publication in cell and gene therapy, lists the world's top 100 thought leaders and opinion shapers who have carried out life-changing work in the biopharmaceutical industry, helping thousands of people across the globe.
Read MoreStemCellRegenMed today announces, as a result of its continued ground-breaking efforts to treat Tay-Sachs disease through stem cell gene therapy, the treatment of three children suffering from this devastating genetic disorder.
Read MoreSynpromics is pleased to announce that Andrei Lyne has joined the company as Chief Financial Officer. The new appointment demonstrates Synpromics's commitment to build a world-class management team to fully exploit its innovative technology.
Read MoreSynpromics announces it incorporation as Scotland's latest biotech company. The new company aims to focus its activities in the area of synthetic mammalian biology and has acquired a number of patent applications submitted by Dr Michael Roberts.
Read More